An interventional study of Cognitive behavioral therapy in ADHD and Behavioral Addiction, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.
Sponsored by University Hospital, Tours · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France — 20 open to participants now, 20 under way, 2 of them phase 3. Attention Deficit Disorder with Hyperactivity · France.
Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, this one is the 39th largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 42 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 71st registered.
1,821 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 297 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →20 of the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 5–12
University Hospital, Brest · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
Nantes University Hospital · Sites in France
Ages 18–99
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 200 Attention Deficit Disorder with Hyperactivity studies recruiting now, 26 (13%) set no upper age limit and 169 (85%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 14 · Phase 4 2
First in 2000; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is below the median of 72 across 1,439 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 80 across the 60 interventional studies, 95 across the 22 observational. Of the 46 that completed or were terminated, 10 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 82 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
5 of the studies in Attention Deficit Disorder with Hyperactivity with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05832489Phase 3University Hospital, Strasbourg, FranceEEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders | 2027-05 |
| NCT06232226Nantes University HospitalAttention Deficit Hyperactivity Disorder | 2026-12-31 |
| NCT07440992Assistance Publique - Hôpitaux de ParisIdentification of Early Biomarkers of Pre-school ADHD | 2027-03-01 |
| NCT07204873University Hospital, GrenobleEvaluation of the LUSHA Digital Application for Children With ADHD - Feasibility Study | 2027-07 |
| NCT06594536Assistance Publique - Hôpitaux de ParisStudy of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity | 2027-08-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies in Attention Deficit Disorder with Hyperactivity with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this pilot study is to assess preliminary data on the feasibility of CBT and its evaluation in a randomised trial in patients with co-occurring ADHD and behavioural addiction: Evaluation and comparison of the 12-week retention rate of patients randomised to CBT compared with patients in the 'treatment as usual' control arm.
In order to meet the objective, the patient will take part in a standardized assessment, followed by a therapeutic intervention and a new standardized assessment after the intervention. The standardized assessment consists as follows :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10 sessions of Cognitive Behavioral Therapy (CBT) Behavioral and Cognitive Therapy (CBT) adapted to comorbidity ADHD/behavioral addiction in remote format (teleconsultation) + routine care (care provided according to the protocols of each center).
Behavioral: Cognitive behavioral therapy
routine care (care performed according to protocols of each center)
Session 1: Functional analysis, motivational approach and psycho-education (advantages/disadvantages of consumption ; effect of addiction on mental disorders and interaction ADHD/behavioral addiction) Session 2: Follow-up to psycho-education session 1, treatment plan Session 3: ADHD: compensation strategies; reducing distractibility distractibility Session 4: ADHD: calendar and organization worksheet Session 5: ADHD: mood disorders and emotions Session 6: Recognizing and managing emotions Session 7: Analysis of functional elements in addictive disorder addictive disorders in patients with ADHD Session 8: Risk situations, psycho-education (emotions) Session 9: Managing craving; analysis of the functional elements of of addiction Session 10: Relapse and relapse prevention, problem solving and social pressure
Retention rate
Proportion of randomized present at the 12-week visit
Time frame: At the 12-week
Adhesion
Number of sessions performed between baseline and 12 weeks,
Time frame: Between baseline and 12 weeks
Adhesion
percentage of patients who attended at least 70% of sessions
Time frame: between baseline and 12 weeks
Quantitative evaluation of acceptance percentage
Number of randomized patients / number of eligible patients eligible patients
Time frame: At 14 weeks
Satisfaction of participants in the Cognitive-behavioural therapy group
only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist (qualitative evaluation)
Time frame: At 14 weeks
Perceived benefits
only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist
Time frame: At 14 weeks
Collection of difficulties during the therapy
only assessed in Cognitive-behavioural therapy group, assessed during an interview with a psychologist
Time frame: At 14 weeks
Assessment of barriers and levers to psychotherapy and cognitive behavioral disorder therapy
Evaluated only for the control group, assessed during an interview with a psychologist
Time frame: At 14 weeks
Assessment of patients' perceived needs in terms of psychotherapy
Evaluated only for the control group, assessed during an interview with a psychologist
Time frame: At 14 weeks
ADHD symptoms
Evaluation will be based on the ASRS-18 (Adult Self-Report Scale) total score. This self-administered questionnaire comprises eighteen questions, six of which are considered to be the most representative of the symptoms associated with ADHD. These six questions, in Part A of the questionnaire, form the core of the ASRS v1.1 screening. Part B contains the remaining twelve questions. The impact of symptoms on different areas of the patient's life is also assessed. Screening is positive when the patient presents at least 4 symptoms with a significant impact among the first 6 items . Each item is rated from 0 to 4, giving a total ASRS-18 score ranging from 0 to 72, with sub-scores for inattention (0 to 36), motor hyperactivity/impulsivity (0 to 20) and verbal hyperactivity/impulsivity (0 to 16).
Time frame: From baseline up to 12 weeks
Quality of life specific to attention-deficit disorder (ADHD)
The Adult ADHD Quality of Life scale (AAQOL) will be used during the assessment phases. This tool has good psychometric qualities and assesses four dimensions of quality of life: productivity in daily life, psychological health, relationships and outlook on life. The AAQOL provides a total quality of life score, as well as 4 sub-scores for each dimension. The total score is between 0 and 100, the sub-dimension scores between 0 and 100 (transformed from responses to each of the responses to each of the 29 items ranging from 1 to 5). The higher the score (total and sub-score), the higher, the better the quality of life
Time frame: From baseline up to 12 weeks
Functional impact of attention deficit hyperactivity disorder (ADHD)
The Weiss Functional Impairment Rating Scale-Self-Report (WFIRS-S) will be used during the assessment phases. This tool, with good psychometric qualities, assesses the impacts of ADHD in seven domains: family, work life, school life, life skills, self-image, social life and risk-taking. Any item rated "2" or "3" is two standard deviations outside the clinical norms for ADHD and is considered impaired. A conservative threshold for defining impairment in any domain is either two items scored '2', or one item scored '3'. The average item score for most domains is '1', with the exception of 'at-risk activities', which is '0.5'. The average score for each of the 7 dimensions is between 0 and 3.
Time frame: From baseline up to 12 weeks
Craving
A visual analog scale (VAS) to assess craving will be used. In the absence of a validated tool to measure craving in a homogeneous way in behavioral addictions, we will ask participants to rate the intensity of craving on a scale from 0 to 10 (0 corresponding to no craving and 10 to maximum craving) and to evaluate the frequency of craving as well as its duration. This type of craving measurement is frequently used in the literature and in addiction research protocols.
Time frame: From baseline up to 12 weeks
Impulsivity
The Impulsive Behavior Scale (UPPS-P) will be used during the assessment phases to measure impulsivity. This tool has good psychometric qualities and measures the following sub-dimensions of impulsivity: positive urgency, negative urgency, lack of premeditation, lack of perseverance and sensation seeking. The score for each dimension ranges from 4 to 16; there is no total score. The higher the score (subscales), the higher the impulsivity.
Time frame: From baseline up to 12 weeks
Emotional dysregulation
The Difficulties in Emotion Regulation Scale (DERS 36) will be used (during the assessment phases) to evaluate emotional dysregulation. With good psychometric qualities, this scale measures 6 dimensions: unacceptance of negative emotions, difficulty engaging in goal-directed behaviors in the presence of negative emotions, difficulty controlling impulsive behaviors in the presence of negative emotions, restricted access to emotion regulation strategies perceived as effective, emotional awareness and lack of understanding of one's emotions, defined as a lack of emotional clarity. The total score ranges from 36 to 180, with sub-dimensions scores ranging from 6 to 30. The higher the score (total scale and subscales), the greater the emotional dysregulation.
Time frame: From baseline up to 12 weeks
Anxiety symptoms
The Hospital Anxiety and Depression scale (HAD) will be used to assess the presence of anxiety and depressive symptoms in participants. This is a variable we wish to control for, in order to verify that anxiety and depressive symptoms are not potential confounding factors in the assessment results. This scale has good psychometric qualities and can be used to assess two dimensions: anxiety symptoms and depressive symptoms. The total score ranges from 0 to 21 for each dimension. For each dimension, the following interpretation can be proposed: \- 7 or less: no symptoms - 8 to 10: moderate score - 11 to 14: average score 15 to 21: severe score. In practice, a threshold score ≥ 11 for each subscale is retained for a significant anxiety or depression score.
Time frame: From baseline up to 12 weeks
Evolution of psychiatric disorders
Evaluation will be based on MINI-S interview (mini international neuropsychiatric interview, simplified )
Time frame: At 12 weeks
Severity of addictive disorders
Evaluation will be based on Clinical Global Impression. The CGI includes two complementary single-item measures that assess the following: (a) severity of psychopathology on a scale of 1 to 7 and (b) change from baseline on a similar treatment on a similar seven-point scale. Following a assessment, the CGI can be completed in less than a minute by an experienced experienced assessor. The CGI is used to gather clinical impressions and track clinical clinical progress over time
Time frame: At 12 weeks
Not enrolling at this site.
Started May 2025 (actual). Primary completion is estimated for Aug 2026, 15 months after the start.
Of 480 non-industry interventional studies with no phase under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 15 months is below that.
Counting every sponsor, half of 511 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Attention Deficit Disorder with Hyperactivity →